Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
about
Interventions for preventing oral candidiasis for patients with cancer receiving treatmentComparison of echinocandin antifungalsAntifungal prophylaxis in pediatric hematology/oncology: new choices & new data.Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.Breakthrough invasive candidiasis in patients on micafungin.Canadian clinical practice guidelines for invasive candidiasis in adults.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Neutropenia Precautions for Children Receiving Chemotherapy or Stem Cell Transplantation for Cancer.Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTsTreatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Echinocandin Resistance in Candida.Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Echinocandin antifungals: review and update.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.A comparative evaluation of properties and clinical efficacy of the echinocandins.Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?Fusarium infection in lung transplant patients: report of 6 cases and review of the literature.Management of fungal infections following allogeneic stem cell transplantation.Guideline for diagnosis, prophylaxis and treatment of invasive fungal infection post burn injury in China 2013Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?Antifungal prophylaxis and treatment in patients with hematological malignancies.Updated guidelines for managing fungal diseases in hematology patients.Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients.Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Invasive candidiasis and candidaemia in neonates and children: update on current guidelines.Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia.Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update.Mechanisms of echinocandin antifungal drug resistance.Trichosporonosis in Pediatric Patients With a Hematologic Disorder.Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients.Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment.Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
P2860
Q24243005-07B02CBD-F13A-4E57-B389-C8C3AAC961CAQ28273738-EBAA4589-A78D-4C9E-9004-48EE99FF040AQ33559503-EB22ECEE-46F7-4596-B9AB-87BED841604CQ33764269-4E2EA746-C3F6-4A01-874C-ACB2D07AAF1EQ33963538-3E66DADD-5943-42A4-B7C1-B95BB3DDD9EDQ34237335-533EECB0-EB6D-4274-A7A9-DA41E5E40439Q34532546-06BD7436-CC11-4118-BBC4-DD9E19163DC0Q35188126-01235820-7397-4192-9929-64DFDEB47EBDQ35515892-2963A4FD-5441-4A36-AC79-69695254FE15Q35959489-AF41C123-2D0A-441C-867F-ABF0EE6A2A9BQ36276186-A95A6C99-EACE-409E-855D-0940E362AEC0Q36406975-6CFCE91C-AB26-4B6A-A5DF-8BB5AB256868Q36441524-CC9BAEE5-B562-4CFB-938A-17C9536F907DQ36626518-7CF6BC6A-125B-4A0E-92C7-66DBC6162234Q36714507-4816EA32-99CB-4B59-B792-78411FD0231FQ36895839-4D6971C5-9D44-4EEA-BF8D-F245888CC5FAQ37015953-C9A6585D-02C5-407A-97DF-DAC3584A15B0Q37098160-AD8572FF-48FB-409F-B803-F7245334C087Q37114436-5E980474-2B23-402A-9B54-642DC03EDBEDQ37202860-B0C1F178-ABC7-43DE-8D24-76C1C2EA1767Q37233505-BE485D85-E61E-40F7-A550-F3675646F184Q37344532-1B5EBF5A-49C8-4DA8-A06B-F0AC4D2F93A6Q37544662-7FE2DB80-D83D-4003-942D-571A80F15169Q37657464-68FDAA17-BA38-4C97-936E-E1ED749AD4D5Q37727168-58117D5D-4612-46A3-B536-01BCEBBC593AQ37785548-6A907062-6B81-48ED-88F2-C7973865B216Q37866827-20A89DD3-3269-4B3C-B890-EDAACC834036Q37993110-3716E654-CFB0-45F3-9D6D-688658292528Q38178526-E1026140-A165-4A5E-812D-C42692C1CFFDQ38222029-1F29A9DE-C323-4251-A83A-363A04A7D44DQ38254290-C232F8C4-1966-453A-AF27-A2AB90717DFBQ38263282-59C22B10-6DBC-4F49-893A-22484A99BD5DQ38264086-D4E2E196-63F9-403F-B74E-08A4951263E1Q38353420-ED5BD149-535A-4E0F-9C36-6801755293E2Q38550402-0FF3AF50-E546-4FB7-ABEB-72AC28BF372CQ38782786-8789F0D4-79E4-48E4-B7CA-8D831D5DB5E2Q40060170-1A5E1787-A0E1-4267-A9D4-F785CD8C5B69Q41673871-979553B4-7B68-4789-A32C-87B98D52310BQ41688288-E01F169E-A53F-4DC7-99DF-0779822A00ECQ42110115-0985EAE5-A729-43CD-AFA9-CF8162C4CC1B
P2860
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Open-label, randomized compari ...... with hematologic malignancies.
@ast
Open-label, randomized compari ...... with hematologic malignancies.
@en
Open-label, randomized compari ...... with hematologic malignancies.
@nl
type
label
Open-label, randomized compari ...... with hematologic malignancies.
@ast
Open-label, randomized compari ...... with hematologic malignancies.
@en
Open-label, randomized compari ...... with hematologic malignancies.
@nl
prefLabel
Open-label, randomized compari ...... with hematologic malignancies.
@ast
Open-label, randomized compari ...... with hematologic malignancies.
@en
Open-label, randomized compari ...... with hematologic malignancies.
@nl
P2093
P2860
P50
P1476
Open-label, randomized compari ...... with hematologic malignancies.
@en
P2093
B Nebiyou Bekele
Elihu H Estey
Francis J Giles
Gladys Alvarado
Gloria N Mattiuzzi
Issam I Raad
Ivonne Lopez-Roman
Luis Ostrosky-Zeichner
P2860
P304
P356
10.1128/AAC.50.1.143-147.2006
P407
P577
2006-01-01T00:00:00Z